2023
Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience
Shabanova V, Emuren L, Gan G, Antwi S, Renner L, Amissah K, Kusah J, Lartey M, Reynolds N, Paintsil E. Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 94: 371-380. PMID: 37643414, PMCID: PMC10617661, DOI: 10.1097/qai.0000000000003292.Peer-Reviewed Original ResearchConceptsHIV disclosure interventionsVirologic outcomesCD4 percentWeek 48HIV statusIntervention groupHIV disclosureDisclosure interventionDetectable viral loadWorld Health OrganizationAntiretroviral therapyImmunologic outcomesClinical outcomesIntervention armViral loadControl armClinical trialsTrial experienceSecondary analysisDisclosure statusHealth OrganizationCategorical variablesWeeksLinear mixed modelsBaseline
2021
“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”
Bade BC, Gan G, Li F, Lu L, Tanoue L, Silvestri GA, Irwin ML. “Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”. BMC Cancer 2021, 21: 352. PMID: 33794808, PMCID: PMC8015735, DOI: 10.1186/s12885-021-08084-0.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced-stage lung cancerStage lung cancerUsual carePhysical activityIntervention groupQuality of lifeLung cancerEligible patientsStage III/IV non-small cell lung cancerLow baseline physical activityHome-based physical activityAdvanced stage diseaseSoluble PD-1Stage IV adenocarcinomaBaseline physical activityMinority of patientsCell lung cancerPatient-reported outcomesEffects of exerciseRole functioning domainsLung cancer biologyAspects of QoL.Mobile health interventionsCancer biomarkers